Atosiban, a synthetic peptide, has a selective action on uterine smooth muscle. Its structure is similar to that of natural oxytocin, but the nature of its action is quite different. atosiban is able to inhibit uterine smooth muscle contractions, and by competing for oxytocin receptors, atosiban is able to display anti-oxytocin effects. Atosiban is mainly used for the treatment of preterm labor, and its mechanism is to inhibit the contraction frequency and strength of uterine smooth muscle, and relax the uterine smooth muscle. Through this action, Atosiban helps delay the onset of preterm labor, providing more time for the mother and fetus to prepare for delivery.
 |
 |
Atosiban is a combined receptor antagonist for both the contractin and pressor V1A receptors, which are structurally similar to the pressor V1A receptor. When the contractin receptor is blocked, the contractin can still act through the V1A receptor, so it is necessary to block the above two receptor pathways with Chemicalbook, a single antagonist of a receptor can effectively inhibit uterine contraction. This is one of the main reasons why beta agonists, calcium channel blockers and prostaglandin synthase inhibitors cannot effectively inhibit uterine contractions.Atosiban, as a combined receptor antagonist of both oxytocin and pressor V1A, has a similar chemical structure and a high affinity for the receptor, and competitively binds to the receptors of both oxytocin and pressor V1A to block the action of the two pathways and reduce uterine contractions. pathway and reduce uterine contractions.
Current R&D Trends at Atosiban
Atosiban's research and development is focused on the following areas:
Expanded clinical applications
In addition to its use in the prevention of preterm labor, researchers are exploring the potential use of Atosiban in other pregnancy-related complications, such as early placental abruption.
Dosage Improvement
Researchers may work to develop more patient-friendly and effective dosage forms, such as oral formulations or long-acting formulations.
Efficacy Enhancement
Ongoing research may aim to improve the efficacy and safety of Atosiban to make it a more widely used drug for the prevention and treatment of preterm labor.
Mechanistic Studies
More in-depth studies of Atosiban's mechanism of action and interaction with the oxytocin receptor will improve understanding of its pharmacologic properties.
Overall, as a drug used for the prevention of preterm labor, the research and development of Atosiban is mainly focused on expanding its clinical application, improving its dosage form, enhancing its efficacy and safety, and conducting in-depth studies on its mechanism of action, so as to satisfy the clinical needs and continue to improve the effectiveness of preterm labor management.
Pharmaceutical Market Trends of Atosiban
China's pharmaceutical intermediates industry has a high degree of marketization, with more small and medium-sized enterprises (SMEs), concentrated production regions, and stable business scale.The market size of China's pharmaceutical intermediates industry was approximately RMB201.7 billion in 2018, down 24% year-on-year, and the industry will return to positive growth in 2020.
In the early stage of the development of the pharmaceutical intermediates industry, due to small investment, profit level is higher than the general chemical products market access threshold is relatively low, a large number of small chemical enterprises to enter the field of pharmaceutical intermediates, which makes the production of rapid growth. 2012 to 2016 China's pharmaceutical intermediates production continued to grow, and in 2017 began to be subject to the environmental protection and safety production policy tightening and industry adjustment and other factors, pharmaceutical intermediates production declined until 2021 when it started to grow again due to the impact of the Xinguan epidemic.China's production of pharmaceutical intermediates in 2021 amounted to 10.32 million tons, which was the same as that of 2018.The production of pharmaceutical intermediates in 2021 is expected to increase by 2020, which is the same as that of 2018.
As pharmaceutical intermediates and chemical APIs are produced in similar ways, Chinese chemical API manufacturers usually also produce pharmaceutical intermediates. China's pharmaceutical intermediates industry is relatively decentralized, most of the enterprises are relatively small in scale. In the future, with the implementation of environmental protection and production safety regulatory policies, enterprises unable to meet the green production will be gradually eliminated, and industry concentration will increase. China's pharmaceutical intermediates accounted for the heaviest enterprises, the main products involved in anti-infectives, anti-tumor, cardiovascular, cerebrovascular, psychotropic and veterinary drugs and other areas, listed on the Shenzhen Stock Exchange in 1997, according to the data show that the company's revenue from intermediates and raw materials showed year-on-year growth trend, the main business of advanced pharmaceutical intermediates, raw materials and related products for the research and development, production and sales, and in 2021 the layout of the The main business is R&D, production and sales of advanced pharmaceutical intermediates, APIs and related products. The main product categories include antiallergic, antithrombotic, antioxidant, gastric ulcer, antiviral, antipyretic and analgesic and ultraviolet absorber, etc. Pharmaceutical intermediates are the main source of income.
 |
 |
The pharmaceutical industry in developed countries in Europe and the United States started earlier, but with the continuous development of global productivity and the deepening of the international division of labor, pharmaceutical companies in developed countries in Europe and the United States are focusing on the research and development of innovative drugs and market development, so that the pharmaceutical intermediates industry is accelerating the transfer to Asian countries, including China and India. In order to meet the continuous development of the pharmaceutical industry, China's pharmaceutical intermediates industry will be from the original low level of repetition, lack of innovation, the traditional mode of crude production to innovation and upgrading, high quality, high level of development, with the advancement of R & D and development, the accumulation of independent intellectual property rights, pharmaceutical intermediates of the added value of the product and the complexity of the process will be continuously improved, becoming a strong guarantee for the development of the pharmaceutical industry.